These two pharma stocks have followed distinct paths of late. Which is the better investment?
This Vanguard growth fund is home to some of the world's most innovative companies.
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
These drugmakers have made important moves over the past year.
Use the recent short-term weakness from these powerhouse companies' stocks to your advantage.
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
It's only a bargain price if it's actually worth owning.